New hope for aggressive lung cancer: drug combo tested in major trial
NCT ID NCT07502300
First seen Mar 30, 2026 · Last updated May 16, 2026 · Updated 8 times
Summary
This study tests a new drug called BL-B01D1 combined with tislelizumab against standard chemotherapy plus tislelizumab for people with extensive-stage small cell lung cancer who have not had treatment before. About 562 adults will take part to see which combination helps them live longer. The goal is to find a more effective first-line option for this aggressive cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan Cancer Hospital
Zhengzhou, Henan, China
Contact
-
Shanghai East Hospital
Shanghai, Shanghai Municipality, China
Contact
Conditions
Explore the condition pages connected to this study.